MYD88 and infection: In this context, while i.p. inoculation of BRD509E (at doses as low as 4 × 102 CFUs/mouse) resulted in high mortality rates in MyD88−/− mice, its oral administration led to the establishment of a chronic infection that lasted for more than 6 months (17).